Literature DB >> 72276

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.

H H Brackmann, J Gormsen.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 72276     DOI： 10.1016/s0140-6736(77)90871-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  24 in total

1.  Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Authors:  Jonathan D Finn; Margareth C Ozelo; Denise E Sabatino; Helen W G Franck; Elizabeth P Merricks; Julie M Crudele; Shangzhen Zhou; Haig H Kazazian; David Lillicrap; Timothy C Nichols; Valder R Arruda
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

3.  High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

Authors:  Christina Hausl; Rafi U Ahmad; Maria Sasgary; Christopher B Doering; Pete Lollar; Günter Richter; Hans Peter Schwarz; Peter L Turecek; Birgit M Reipert
Journal:  Blood       Date:  2005-08-09       Impact factor: 22.113

4.  Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.

Authors:  V Pascual; J D Capra
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

5.  Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.

Authors:  D H Parry; A L Bloom
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

Review 6.  Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

Authors:  Emilie M J van Brummelen; Willeke Ros; Gertjan Wolbink; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2016-07-20

Review 7.  Gene therapy for immune tolerance induction in hemophilia with inhibitors.

Authors:  V R Arruda; B J Samelson-Jones
Journal:  J Thromb Haemost       Date:  2016-05-14       Impact factor: 5.824

8.  Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

Authors:  D P O'Brien; A R Giles; K M Tate; G A Vehar
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

9.  Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.

Authors:  Stephanie Planque; Miguel A Escobar; Keri C Smith; Hiroaki Taguchi; Yasuhiro Nishiyama; Elizabeth Donnachie; Kathleen P Pratt; Sudhir Paul
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

10.  [Different proportions of factor VIII and factor VIII inhibitors in their antigen-antibody complexes].

Authors:  G Hintz; R Schwerdtfeger
Journal:  Blut       Date:  1982-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.